|
|
Previous Article | Table of Contents | Next Article 
Increased numbers of long-term culture-initiating cells in the apheresis
product of patients randomized to receive increasing doses of stem cell
factor administered in combination with chemotherapy and a standard dose of
granulocyte colony-stimulating factor
A Weaver, D Ryder, D Crowther, TM Dexter and NG Testa
Cancer Research Campaign Department of Experimental Haematology, Christie
Hospital, Manchester, UK.
Long-term culture-initiating cells (LTC-IC) are arguably the most primitive
human hematopoietic cells detectable by in vitro functional assays. We have
investigated the mobilization of these cells into the blood of patients
with ovarian carcinoma randomized to receive granulocyte colony-stimulating
factor (G-CSF; 5 micrograms/kg) plus different doses of stem cell factor
(SCF; c-kit ligand) after chemotherapy or G-CSF alone after chemotherapy.
We have shown a significant SCF dose response for the mobilization of
LTC-IC, with a 5.8-fold increase in LTC-IC mobilization in those patients
receiving chemotherapy, G-CSF, and 20 micrograms/kg of SCF, the highest
dose used, compared with the patients receiving chemotherapy and G-CSF
alone. We have shown a threefold increase in CD34+ cells and up to a 64-
fold increase in CD34+/33- cells was seen in patients treated with
chemotherapy, G-CSF, and 20 micrograms/kg of SCF compared with those
patients treated with chemotherapy and G-CSF alone. However, significant
numbers of CD34+/38- cells were only found in the patients receiving 20
micrograms/kg of SCF as part of their mobilization regimen. Patients
receiving chemotherapy plus G-CSF and SCF have enhanced mobilization of
primitive cells and of the more committed progenitor cells compared with
those patients receiving chemotherapy followed by G-CSF alone.
Volume 88,
Issue 9,
pp. 3323-3328,
11/01/1996
Copyright © 1996 by The American Society of Hematology

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Zeuner, F. Pedini, M. Signore, U. Testa, E. Pelosi, C. Peschle, and R. De Maria
Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins
Blood,
July 1, 2003;
102(1):
87 - 93.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Hematti, S. E. Sellers, B. A. Agricola, M. E. Metzger, R. E. Donahue, and C. E. Dunbar
Retroviral transduction efficiency of G-CSF+SCF-mobilized peripheral blood CD34+ cells is superior to G-CSF or G-CSF+Flt3-L-mobilized cells in nonhuman primates
Blood,
March 15, 2003;
101(6):
2199 - 2205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella
Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy
J. Clin. Oncol.,
March 13, 2000;
18(6):
1360 - 1377.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Facon, J.-L. Harousseau, F. Maloisel, M. Attal, J. Odriozola, A. Alegre, W. Schroyens, C. Hulin, R. Schots, P. Marin, et al.
Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial
Blood,
August 15, 1999;
94(4):
1218 - 1225.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. A. Franklin, J. Glaspy, S. M. Pflaumer, R. B. Jones, L. Hami, C. Martinez, J. R. Murphy, and E. J. Shpall
Incidence of Tumor-Cell Contamination in Leukapheresis Products of Breast Cancer Patients Mobilized With Stem Cell Factor and Granulocyte Colony-Stimulating Factor (G-CSF) or With G-CSF Alone
Blood,
July 1, 1999;
94(1):
340 - 347.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Erben, E. Thiel, and M. Notter
Differential Effects of a Stem Cell Factor-Immunoglobulin Fusion Protein on Malignant and Normal Hematopoietic Cells
Cancer Res.,
June 1, 1999;
59(12):
2924 - 2930.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Shpall, C. A. Wheeler, S. A. Turner, S. Yanovich, R. A. Brown, A. L. Pecora, T. C. Shea, K. F. Mangan, S. F. Williams, C. F. LeMaistre, et al.
A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients
Blood,
April 15, 1999;
93(8):
2491 - 2501.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. H. Nocka, B. A. Levine, J.-L. Ko, P. M. Burch, B. E. Landgraf, R. Segal, and R. Lobell
Increased Growth Promoting But Not Mast Cell Degranulation Potential of a Covalent Dimer of c-Kit Ligand
Blood,
November 15, 1997;
90(10):
3874 - 3883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.G. Begley, R. Basser, R. Mansfield, B. Thomson, W.R.L. Parker, J. Layton, B. To, J. Cebon, W.P. Sheridan, R.M. Fox, et al.
Enhanced Levels and Enhanced Clonogenic Capacity of Blood Progenitor Cells Following Administration of Stem Cell Factor Plus Granulocyte Colony-Stimulating Factor to Humans
Blood,
November 1, 1997;
90(9):
3378 - 3389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.A. Glaspy, E.J. Shpall, C.F. LeMaistre, R.A. Briddell, D.M. Menchaca, S.A. Turner, M. Lill, L. Chap, R. Jones, M.D. Wiers, et al.
Peripheral Blood Progenitor Cell Mobilization Using Stem Cell Factor in Combination With Filgrastim in Breast Cancer Patients
Blood,
October 15, 1997;
90(8):
2939 - 2951.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. P. Schofield, G. Rushton, M. J. Humphries, T. M. Dexter, and J. T. Gallagher
Influence of Interleukin-3 and Other Growth Factors on alpha 4beta 1 Integrin-Mediated Adhesion and Migration of Human Hematopoietic Progenitor Cells
Blood,
September 1, 1997;
90(5):
1858 - 1866.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. C. Broudy
Stem Cell Factor and Hematopoiesis
Blood,
August 15, 1997;
90(4):
1345 - 1364.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Papayannopoulou, B. Nakamoto, R. G. Andrews, S. D. Lyman, and M. Y. Lee
In Vivo Effects of Flt3/Flk2 Ligand on Mobilization of Hematopoietic Progenitors in Primates and Potent Synergistic Enhancement With Granulocyte Colony-Stimulating Factor
Blood,
July 15, 1997;
90(2):
620 - 629.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|